Synergy suffers from constipation of cash?
已更新
Very good news came for Synergy pharmaceuticals, the FDA approved expanded indication to treat irritable bowel for one of their products.
However, according to some analysts seems that the company suffers from cash constipation (lol) which limits its access to loans with which it could exploit this product to the maximum.
I think it is quite interesting what can happen with this company in the next few days, I will be pending how it develops, obviously everything will depend on the level of certainty that may generate in investors, words like cash, loans and strategies will be key.
However, according to some analysts seems that the company suffers from cash constipation (lol) which limits its access to loans with which it could exploit this product to the maximum.
I think it is quite interesting what can happen with this company in the next few days, I will be pending how it develops, obviously everything will depend on the level of certainty that may generate in investors, words like cash, loans and strategies will be key.
註釋
Nop, not good.交易結束：達到停損點
免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。